EC Number   |
Application |
Reference  |
|---|
    3.2.1.51 | medicine |
recombinant enzyme will extend the proven efficiacy of enzyme replacement therapy in lysosomal storage disorders e.g. fucosidosis |
208694 |
| 3.2.1.51 | analysis |
studies of structures and functions of glycoconjugates and oligosaccharides due to unique substrate specificity |
208702 |
| 3.2.1.51 | medicine |
the differentiation of HT-29 colon cancer cells can be used as a model to study the alteration of the enzyme alpha-L-fucosidase during the progression of the tumoural processs |
655733 |
| 3.2.1.51 | medicine |
deficiency in enzyme activity is associated with fucosidosis |
656203 |
| 3.2.1.51 | diagnostics |
serum alpha-L-fucosidase is a useful marker in the diagnosis of hepatocellular carcinoma. The assay has high sensitivity and specificity. The procedure is simple, rapid, convenient, and can be adapted to automated clinical analyzers for use in large scale screening for early diagnosis of hepatocellular carcinoma |
664629 |
| 3.2.1.51 | analysis |
comparison of glycolytic and chitinolytic enzyme activities between desert and oasis flies of Phlebotomus papatasi to evaluate potential differences in susceptibility to infection with Leishmania major |
679943 |
| 3.2.1.51 | medicine |
quality of semen is affected in part by the loss in the activity of alpha-fucosidase, which may be useful in early diagnosis of the loss in reproductive capacity during the course of trypanosomiasis and fertility tests |
680897 |
| 3.2.1.51 | medicine |
has a role in the intimate species signature interactions between sperm and oocyte. Relevance for reproductive function in nature or in assisted reproductive technologies |
682040 |
| 3.2.1.51 | medicine |
may be useful as a biomarker for predicting the progression-free survival of for trastuzumab treatment |
699825 |
| 3.2.1.51 | medicine |
progression-free survival significantly longer in high FUCA activity group than in low FUCA activity group, not correlated to clinical response to trastuzumab but maybe useful as biomarker for predicting progression-free survival for trastuzumab treatment, serum FUCA activity correlates with early detection in hepatocellular carcinoma |
699825 |
